BioSpace News Archive

Neurocrine Biosciences, Inc. will present at the virtual 40th Annual J.P. Morgan Healthcare Conference at 11:15 a.m. Eastern Time on Monday Jan. 10, 2022.

Renovacor, Inc. announced that Magdalene Cook, M.D., President and Chief Executive Officer of Renovacor, will participate in a panel presentation at the 11th Annual LifeSci Partners Corporate Access Event.

Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 fourth quarter financial results after the close of the market on Thursday, February 24th.

AngioDynamics, Inc., a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 24th Annual Needham Virtual Growth Conference at 2:00 p.m.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Exclusivity (ODE) for Xywav®.

ImmunoGen Inc. announced that on December 31, 2021 the compensation committee of the Company’s Board of Directors granted a non-qualified stock option award to purchase 16,800 shares of its common stock to a new employee under the ImmunoGen, Inc. Inducement Equity Incentive Plan.

Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced that Alan Fuhrman, Interim CEO and President, will present at the H.C. Wainwright BioConnect Virtual Conference being held on January 10-13, 2022.

ANI Pharmaceuticals, Inc. announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference as follows.

Chimerix announced that Company management, including Mike Sherman, Chief Executive Officer, and Mike Andriole, Chief Business and Financial Officer, will participate in a pre-recorded fireside chat at the H.C. Wainwright BioConnect 2022 Conference made available on Monday, January 10, 2022 at 7:00 a.m. ET.

Everest Medicines Limited (HKEX 1952.HK, “Everest”, or the “Company”),announced today that Taiwan Food and Drug Administration (TFDA) has accepted the submission of a New Drug Application (NDA) for sacituzumab govitecan (SG).